Innovative MS Treatment Unveiled by ADSCC in Abu Dhabi

Post by : Mara Rahim

The Abu Dhabi Stem Cells Centre (ADSCC) has introduced an innovative treatment for Multiple Sclerosis (MS) utilizing the THERAKOS CELLEX platform for photopheresis. This new therapy is part of a clinical trial sanctioned by the Department of Health – Abu Dhabi, offering a fresh possibility for those affected by this complex neurological condition, enhancing their quality of life and offering improved symptom management.

MS is a chronic illness wherein the immune system attacks the nervous system, leading to difficulties in movement, balance, and communication. Despite existing therapies, many patients find that traditional treatments eventually lose their effectiveness. Therefore, there is a pressing demand for new therapeutic options. The extracorporeal photopheresis (ECP) approach developed by ADSCC presents hope for patients left with few viable alternatives.

ECP has been previously applied to treat conditions like graft-versus-host disease and certain lymphoma types. For MS patients, the procedure entails drawing a patient's white blood cells, applying light therapy externally, and then reintroducing these cells into the patient. This method is geared towards rebalancing the immune system, which might slow MS progression and alleviate symptoms such as walking difficulties, instability, and speech impairments.

This treatment is part of the PHOMS clinical study spearheaded by ADSCC and approved by the Department of Health – Abu Dhabi, focusing on individuals with Secondary Progressive MS and Relapsing-Remitting MS. Numerous participants have reported positive changes in their mobility, balance, and speech, showcasing potential advancements that standard therapies failed to deliver. These encouraging outcomes suggest that photopheresis might be a groundbreaking choice for those living with MS.

Prof. Yendry Ventura, CEO of ADSCC, emphasized the collaborative efforts among key players in Abu Dhabi's healthcare framework, including the DOH and the MS Society, as vital to the trial's achievements. He indicated that forthcoming results may set the stage for worldwide adoption of this novel MS treatment, reinforcing the UAE’s status as a frontrunner in cell and gene therapy.

Sandra Thompson, Co-CEO of Therakos LLC, commended the commitment and knowledge of ADSCC. She remarked that this alliance would facilitate significant advancements for the MS community in the UAE. This partnership aims to fuse scientific innovation with patient-centered research, enhancing treatment results and bolstering hope for those affected by MS.

The initiation of this advanced therapy signifies a pivotal advancement for the worldwide MS community. By marrying scientific precision, technological innovation, and patient care, the UAE is opening a new pathway of hope for those grappling with a challenging and often life-altering condition. With ongoing research and collaboration, photopheresis has the potential to evolve into a standard treatment modality for MS, delivering relief and an improved quality of life for patients everywhere.